New hope for aggressive breast cancer: experimental drug ESG401 enters final testing phase
NCT ID NCT06732323
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial is testing a new drug called ESG401 against standard chemotherapy for people with advanced triple-negative breast cancer that has spread or come back. The study will enroll about 504 participants to see if ESG401 can delay cancer growth and improve survival. It's an open-label study, meaning everyone knows which treatment they are getting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ESG401 (a drug given by IV infusion)
What this could lead to
If successful, ESG401 could offer a new first-line treatment option for people with metastatic triple-negative breast cancer, potentially improving how long they live without their cancer getting worse.
What could go wrong
This is a Phase 3 trial, but it's still experimental. ESG401 may not prove better than existing chemotherapies, and it could have side effects. Results are not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••